PROs in regulatory decision making
The Lancet Oncology in conversation with
English - April 25, 2018 14:30 - 11 minutes - 7.99 MB - ★★★★★ - 1 ratingMedicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Vulvar field resection
Next Episode: Gender and cancer immunotherapy efficacy
Paul Kluetz from the US FDA discusses the issues surrounding the use of patient-reported outcomes in regulatory decision making.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv